Efalizumab (Raptiva), an investigational therapy for moderate-to-severe psoriasis, achieved its primary efficacy endpoint in a randomized phase III study.
ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment
Retinoic Acid, Vitamin A Demonstrates Role in Regulating Hair Follicles and Epidermal Stem Cells
ReV Up Your Vitiligo Treatment Strategies
LC-OCT Demonstrates Potential For Rapid, Effective Visualization of Inflammatory Conditions Across Skin Types
Tristan Hasbargen, PA-C: Closure Types in Mohs Surgery and More